A clip from HHS Secretary Robert F. Kennedy Jr.’s recent Joe Rogan Experience appearance has been making the rounds in the peptide and broader wellness industries. The headline is Kennedy said he wants to move about fourteen peptides that are currently treated as “Category 2” back into “Category 1,” and he framed the original move into Category 2 as being not supported by an actual safety risk.
The Regulatory Buzz around Category 2
That point is exciting and controversial as “Category 2” has historically functioned in clinical and pharmacy practice like a scarlet letter. It’s the bucket FDA has used to communicate that certain bulk drug substances present “significant safety risks” when used in human drug compounding, and, even when prescribed or dispensed under a legitimate provider-patient relationship with regulated quality sourcing, have still been grounds for state board disciplinary action. When peptides land there, regulated clinical access gets squeezed, compounding partners get nervous because they are at risk for dispensing them, clinics get increasingly cautious to prescribe them, and everyone starts asking whether it’s even worth touching, even with the meaningful and demonstrated positive patient impacts that providers and pharmacies have witnessed in patient care.
When Regulatory Supply Shrinks, Demand Doesn’t Disappear
Kennedy’s thesis was essentially that if there wasn’t a real safety signal that warranted the restriction in the first place, then keeping these peptides in Category 2 doesn’t actually protect patients, but it just pushes demand into places that are harder to supervise from a regulatory and quality standpoint. He said the black market opened up, and he wants to do something about it.
A lot of policymakers significantly underestimate this part, though most operators understand it instinctively. If you remove regulated supply without removing demand, you don’t get “less use”. People don’t wait for regulators to change their minds. Instead, you get different and inconsistent channels. Patients don’t stop searching. Clinicians don’t stop getting asked about them. The only thing that changes is whether access flows through inspected, accountable infrastructure or through workarounds with minimal oversight and unclear incentives.
If these peptides really do move back into Category 1, it would reroute access for many back toward licensed clinical decision-making, medical records, pharmacy controls, quality systems, and regulated product traceability. It also changes consumer behavior in a way people aren’t talking about enough. A lot of RUO demand is not ideological. It’s logistical. When something isn’t available through normal clinical channels, consumers drift into self-directed purchasing and reconstitution. But when that same therapy becomes accessible again through telehealth and clinic models, where there’s dosing guidance, monitoring, and continuity of care, a meaningful segment will pivot back. Not because people suddenly became compliance purists, but because most people would rather not guess if there is an option for clinical guidance. That said, it’s still not a universal swing back. Another meaningful subset of the public has also lost faith in traditional clinical leadership, cannot find enough providers who are knowledgeable enough in the wellness space, and others simply don’t want to pay for clinical guidance or deal with insurance companies on top of supply costs, so access will still fragment across channels even if “Category 1” availability expands.
What we still don’t have, though, is the part everyone wants most: which peptides, when, and through what formal FDA action. Until there’s something in writing from FDA, anyone claiming to have “the list” is either speculating or selling something.
Quality and Accountability Will Continue to Matter Most Regardless of the Delivery Platform
Even if regulated clinical pathways expand, consumer-facing models may still exist, but the long term winners will be the channels that can demonstrate sourcing integrity, transparency, and appropriate quality guardrails, and that invest in sustainable, differentiating product and manufacturing safety measures.
And even if the reclassification happens, the work doesn’t end there. Moving a substance back into a more permissive bucket doesn’t eliminate quality risk, but it actually raises the stakes. More access means more volume, more attention, more patient exposure, and more scrutiny. Manufacturers, compounders, clinics, and third-party platforms should treat this moment as a prompt to tighten, not loosen, quality systems, supplier qualification, documentation, complaint handling, and marketing discipline.
If we want a world where the public can access these therapies safely, this is what it looks like: consistent and streamlined channels that can be audited, inspected, and held accountable. If Kennedy is right that there wasn’t a real safety basis for the Category 2 posture of these peptides, then correcting that posture is not a ‘gift to the industry,’ but a course correction that recognizes these peptides are not as dangerous as they’ve been positioned—when used correctly.
